Antibody-Drug Conjugates – Page 2

Otsuka’s Taiho pays $400M for Swiss partner to ‘turbocharge’ 3 ADCs to clinic

5 months ago talkbio0Tagged Acquisition (action), ADC, ADCs, Antibody-Drug Conjugates, Araris, Otsuka 's, Taiho

Araris, Taiho, Antibody-Drug Conjugates, Otsuka ‘s, Acquisition (action), ADCs, ADC

ImmunoPrecise Antibodies Secures $8-10M Partnership for Novel Cancer Therapeutics Development

6 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, B-cell Select ™ technology, Cancer Therapeutic Procedure, Discover, ImmunoPrecise Antibodies, Immunostimulating conjugate (antigen)

ImmunoPrecise Antibodies, Antibody-Drug Conjugates (ADCs), bispecific antibodies, cancer treatment, AI-driven discovery, B-cell Select™ technology

Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations

6 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, Clinical Trials, Ivonescimab, PD-1/VEGF, Pfizer, Solid Neoplasm, summit

Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials

Radiance Biopharma Secures $1.2 Billion Deal for Novel ROR1-Targeted Antibody-Drug Conjugate from CSPC

6 months ago talkbio0Tagged Antibody-Drug Conjugates, biopharmaceutical partnership, Dosage Forms, GZMH gene, Neoplasms, Radiance Biopharma, ROR1 protein, human

Radiance Biopharma, CSPC Pharmaceutical, ROR1, antibody-drug conjugate (ADC), oncology, licensing deal, biopharmaceutical partnership

Corbus’ Nectin-4 ADC Shows Promise in Western Study, Challenging Pfizer’s Padcev

6 months ago talkbio0Tagged Antibody-Drug Conjugates, ASCO-GU, Cancer of Neck, Clinical Trials, Corbus Pharmaceuticals, CRB-701, NECTIN4 gene, Padcev, urothelial cancer

Corbus Pharmaceuticals, CRB-701, antibody-drug conjugate, Nectin-4, urothelial cancer, head and neck cancer, Padcev, clinical trial, ASCO-GU 2025

FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma

6 months ago talkbio0Tagged Adcetris, Antibody-Drug Conjugates, Approved, BRENTUXIMAB, Combined Modality Therapy, Diffuse Large B-Cell Lymphoma, LBCL, Pfizer, United States Food and Drug Administration, vedotin

Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy

ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma

7 months ago talkbio0Tagged Antibody-Drug Conjugates, ArriVent, Biopharma, Lepu Biopharma, Malignant neoplasm of gastrointestinal tract, MRG007

ArriVent BioPharma, Lepu Biopharma, MRG007, Antibody Drug Conjugate (ADC), Gastrointestinal Cancers, Exclusive License Agreement

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

7 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)

Daiichi Sankyo Expands Cancer Research and Manufacturing Capacity in Germany

7 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Cancer Research, Capacity, Daiichi, Germany, innovation, Manufacturing, Pfaffenhofen facility, Sankyo

Daiichi Sankyo, antibody-drug conjugates (ADCs), cancer research, manufacturing capacity, Germany, Pfaffenhofen facility, innovation center

Roche’s Chugai Enters $780M Deal with Swiss ADC Specialist Araris Biotech

8 months ago talkbio0Tagged Antibody-Drug Conjugates, Araris, biotech, Chugai, Roche (company), therapeutic autologous dendritic cells

Roche, Chugai, Araris Biotech, ADC, Antibody-Drug Conjugate, Biotech Deal